Pakistan CCRA Cannabis Regulations: Commercial Framework and Compliance

Executive Summary

Pakistan approved the Cannabis Control and Regulatory Authority (CCRA) Rules 2026 on July 3, 2026, establishing the legal framework for commercial cannabis cultivation, processing, and export. The regulations mark a historic shift for a country where cannabis has grown wild for centuries but remained legally prohibited for decades under the Prohibition (Enforcement of Hadd) Order, 1979 and the Control of Narcotic Substances Act, 1997. The CCRA Rules create a licensing regime for industrial hemp and medicinal cannabis, targeting pharmaceutical and textile export markets while maintaining criminal penalties for recreational use. Pakistan joins a growing list of Asian nations exploring regulated cannabis frameworks, following Thailand's 2022 decriminalization and Israel's established medical program. The rules establish cultivation zones in Khyber Pakhtunkhwa and Balochistan, set THC limits at 0.3% for hemp, and require all licensees to register with the newly formed CCRA under the Ministry of Narcotics Control.

The regulations arrive as Pakistan seeks new agricultural export revenue streams amid ongoing economic challenges. The country's northern regions have produced high-quality cannabis landraces for generations, including the renowned Chitral and Hindu Kush varieties. The CCRA framework attempts to channel this traditional cultivation into legal, taxed commerce while satisfying international treaty obligations under the 1961 Single Convention on Narcotic Drugs. Initial licenses will focus on pharmaceutical-grade CBD extraction and hemp fiber production, with the government projecting $1 billion in annual export revenue within five years.

The approval follows three years of legislative debate and stakeholder consultation. The Ministry of Narcotics Control drafted the rules in coordination with the Ministry of National Health Services, the Pakistan Agricultural Research Council, and provincial agriculture departments. Civil society organizations raised concerns about enforcement capacity and potential diversion to illicit markets, while agricultural advocates emphasized economic opportunity for rural farmers in underdeveloped regions.

Why This Matters

Pakistan's CCRA Rules affect 240 million citizens, position the country to compete in a global legal cannabis market projected to reach $57 billion by 2027, and could reshape agricultural policy across South Asia. The regulations create immediate opportunities for pharmaceutical companies, textile manufacturers, and contract farmers while establishing precedent for cannabis policy reform in Muslim-majority nations.

For patients and medical stakeholders, the rules authorize domestic production of cannabis-derived medicines, potentially reducing import costs for CBD-based epilepsy treatments and pain management products. Pakistan's pharmaceutical sector, valued at $3.5 billion annually, gains access to raw materials previously available only through expensive imports or illegal channels. The Aga Khan University Hospital and Shaukat Khanum Memorial Cancer Hospital have expressed interest in clinical trials for cannabis-based therapies, pending CCRA research licenses.

For farmers and agricultural workers, the program offers legal income alternatives in regions with limited economic options. Khyber Pakhtunkhwa and Balochistan provinces, where poppy cultivation has historically competed with legal crops, receive designated cultivation zones under the rules. The Ministry of Narcotics Control estimates 50,000 farming families could participate in licensed cannabis cultivation within three years, generating rural employment in processing and transportation sectors.

For businesses and investors, the CCRA framework opens Pakistan's market to domestic and foreign capital. The rules permit foreign direct investment in licensed facilities with Pakistani majority ownership requirements. Textile manufacturers in Faisalabad and Karachi have already announced plans to integrate hemp fiber into export production lines. International pharmaceutical companies including Hikma Pharmaceuticals and Abbott Laboratories Pakistan have initiated discussions with the CCRA regarding API production licenses.

For law enforcement and regulators, the rules create new compliance and monitoring obligations. The Anti-Narcotics Force must distinguish legal licensed cultivation from illegal operations, requiring training, technology investment, and coordination with provincial police forces. The CCRA will employ approximately 500 inspectors and administrators to oversee the licensing system, track-and-trace requirements, and quality control testing.

Regionally, Pakistan's move influences policy debates in neighboring countries. Afghanistan's Taliban government has banned all cannabis cultivation despite historical production. India maintains prohibition under the Narcotic Drugs and Psychotropic Substances Act, 1985, though some states permit traditional bhang consumption. Bangladesh and Iran watch Pakistan's implementation closely as they consider their own regulatory frameworks.

Background and History

Pakistan's relationship with cannabis spans millennia of traditional use, colonial-era regulation, post-independence prohibition, and recent reconsideration driven by economic necessity and global policy shifts.

Pre-Colonial and Colonial Era (Ancient Times - 1947)

Cannabis has grown wild across Pakistan's northern mountainous regions for thousands of years, with archaeological evidence of use dating to the Indus Valley Civilization. Traditional preparations including charas (hand-rolled hashish) and bhang (cannabis-infused beverage) featured in Sufi religious practices and Ayurvedic medicine throughout the region. The plant held cultural significance in Pashtun and Baloch communities, where it served medicinal, recreational, and economic purposes.

British colonial authorities regulated cannabis under the Indian Hemp Drugs Commission Report of 1894, which concluded that moderate cannabis use posed little harm and recommended taxation rather than prohibition. The colonial government imposed excise duties on cannabis sales while permitting licensed cultivation and retail. This regulatory approach continued through the early 20th century, with cannabis available in government-licensed shops alongside opium and alcohol.

Post-Independence Prohibition (1947-2000)

Following independence in 1947, Pakistan initially maintained British-era cannabis regulations. The situation changed dramatically in 1979 when General Muhammad Zia-ul-Haq's military government enacted the Prohibition (Enforcement of Hadd) Order, 1979, which banned alcohol and narcotic substances as part of Islamization policies. The order prescribed harsh penalties including flogging and imprisonment for cannabis possession and sale.

Pakistan further strengthened prohibition by enacting the Control of Narcotic Substances Act, 1997, which classified cannabis as a narcotic substance alongside heroin and cocaine. The act established the Anti-Narcotics Force as the primary enforcement agency and set penalties of up to 25 years imprisonment for cultivation and trafficking. The law made no distinction between hemp and psychoactive cannabis varieties, effectively criminalizing all Cannabis sativa cultivation.

Despite legal prohibition, cannabis cultivation persisted in remote areas of Khyber Pakhtunkhwa, Federally Administered Tribal Areas, and Balochistan. The United Nations Office on Drugs and Crime estimated Pakistan produced 1,500 to 2,500 metric tons of hashish annually throughout the 1990s and 2000s, making it one of the world's largest producers. Most production occurred in areas with limited government control, and proceeds often funded militant groups and tribal conflicts.

International Treaty Obligations and Pressure (1961-Present)

Pakistan became a signatory to the 1961 Single Convention on Narcotic Drugs and its 1972 Protocol, which required parties to limit cannabis to medical and scientific purposes. The country also signed the 1971 Convention on Psychotropic Substances and the 1988 Convention Against Illicit Traffic in Narcotic Drugs. These treaties shaped Pakistan's domestic prohibition policies and created international reporting obligations to the International Narcotics Control Board.

The United States designated Pakistan as a major drug transit country and provided funding for eradication programs through the State Department's International Narcotics Control Strategy Report. Between 2000 and 2020, Pakistan received approximately $150 million in U.S. counternarcotics assistance, much of it directed toward cannabis and opium eradication in tribal areas. This international pressure reinforced domestic prohibition even as global attitudes toward cannabis began shifting.

Economic Crisis and Policy Reconsideration (2018-2023)

Pakistan's economic challenges in the late 2010s and early 2020s prompted reconsideration of cannabis policy. The country faced recurring balance of payments crises, requiring multiple International Monetary Fund bailout programs. Agricultural exports stagnated while import bills for pharmaceuticals and textiles rose. Government officials began examining cannabis legalization as a potential revenue source.

In 2020, Senator Sehar Kamran of the Pakistan Tehreek-e-Insaf party introduced a private member's bill proposing industrial hemp legalization. The bill cited economic benefits observed in Canada, Uruguay, and U.S. states that had legalized cannabis. The Ministry of Narcotics Control commissioned a feasibility study from the Pakistan Agricultural Research Council, which concluded that regulated cannabis cultivation could generate $1 billion to $4 billion in annual export revenue.

The COVID-19 pandemic accelerated interest in pharmaceutical self-sufficiency. Pakistan imported approximately $400 million in pharmaceutical raw materials annually, including some cannabinoid-based medicines for epilepsy treatment. Domestic production of these compounds became a policy priority as supply chains disrupted and foreign exchange reserves declined.

Legislative Development (2023-2026)

The National Assembly passed the Cannabis Control and Regulatory Authority Act, 2023 in November 2023, establishing the legal foundation for regulated cannabis. The act created the CCRA as an autonomous body under the Ministry of Narcotics Control with authority to issue licenses, set quality standards, and enforce compliance. The legislation distinguished between industrial hemp (defined as cannabis with THC content below 0.3%) and medicinal cannabis (higher THC content for pharmaceutical use), permitting both under strict licensing.

The act required the CCRA to draft implementing regulations within 30 months. The authority conducted stakeholder consultations with provincial governments, agricultural organizations, pharmaceutical companies, law enforcement agencies, and civil society groups between 2024 and 2026. Key debates centered on THC limits, cultivation zones, foreign investment restrictions, and enforcement mechanisms.

The Ministry of Religious Affairs issued a fatwa in March 2025 clarifying that industrial and medicinal cannabis use did not violate Islamic principles when properly regulated and limited to non-intoxicating purposes. This religious guidance addressed concerns from conservative political parties and helped build consensus for the regulatory framework.

CCRA Rules 2026 Approval

The CCRA Board of Directors finalized the CCRA Rules 2026 in June 2026 after incorporating public comments from a 60-day consultation period. The Ministry of Narcotics Control approved the rules on July 3, 2026, with immediate effect. The regulations span 247 pages and cover licensing procedures, cultivation standards, processing requirements, quality control protocols, security measures, and penalties for violations.

Key Players

Cannabis Control and Regulatory Authority (CCRA)

The CCRA serves as the primary regulatory body with authority to license, inspect, and enforce compliance across Pakistan's legal cannabis sector. Established under the Cannabis Control and Regulatory Authority Act, 2023, the authority operates as an autonomous organization under the Ministry of Narcotics Control. The CCRA Board includes representatives from the Ministry of Narcotics Control, Ministry of National Health Services, Ministry of Commerce, provincial agriculture departments, and three independent experts in pharmacology, agriculture, and law enforcement.

Major General (Retired) Tariq Khan chairs the CCRA Board, bringing experience from his previous role as Inspector General of the Frontier Corps. The authority maintains headquarters in Islamabad with regional offices planned for Peshawar, Quetta, Lahore, and Karachi. The CCRA's initial budget of 2 billion Pakistani rupees (approximately $7 million) funds licensing systems, laboratory facilities, and inspector training programs.

Ministry of Narcotics Control

The Ministry of Narcotics Control oversees the CCRA and coordinates cannabis policy with international treaty obligations. Minister Mohsin Raza Naqvi has publicly supported regulated cannabis as an economic development tool while emphasizing continued prohibition of recreational use. The ministry manages Pakistan's relationships with the International Narcotics Control Board and submits required reports on licensed cultivation and production volumes.

Anti-Narcotics Force (ANF)

The ANF enforces criminal penalties for unlicensed cannabis cultivation and trafficking while coordinating with the CCRA to distinguish legal from illegal operations. The force operates under the Ministry of Narcotics Control and maintains approximately 3,500 personnel nationwide. Director General Major General Muhammad Aniq Ur Rehman Malik has stated that the ANF will prioritize training officers to identify licensed cultivation sites and verify CCRA documentation during field operations.

Provincial Agriculture Departments

Provincial governments in Khyber Pakhtunkhwa and Balochistan play crucial roles in implementing the CCRA Rules within designated cultivation zones. The Khyber Pakhtunkhwa Agriculture Department has identified 12 districts suitable for licensed hemp cultivation, including Chitral, Dir, and Swat. The Balochistan Agriculture Department designated areas in Pishin, Zhob, and Loralai districts. Provincial authorities coordinate with the CCRA on farmer registration, extension services, and crop monitoring.

Pakistan Agricultural Research Council (PARC)

PARC conducts research on cannabis genetics, cultivation techniques, and pest management to support licensed farmers. The council maintains a germplasm bank of Pakistani cannabis landraces and develops certified seed varieties meeting CCRA THC limits. PARC's National Agricultural Research Centre in Islamabad houses the primary cannabis research facility, with satellite stations in Mingora and Quetta.

Pharmaceutical Industry

Pakistan's pharmaceutical sector represents the primary market for medicinal cannabis production. The Pakistan Pharmaceutical Manufacturers Association has engaged with the CCRA regarding API production licenses and good manufacturing practice standards. Major companies including Getz Pharma, Searle Pakistan, and Ferozsons Laboratories have announced interest in cannabis-derived medicine production pending regulatory approval.

Textile Manufacturers

The All Pakistan Textile Mills Association views hemp fiber as a sustainable alternative to cotton and synthetic materials. Pakistan's textile sector contributes approximately 60% of export earnings, and manufacturers seek to diversify raw material sources. The association has lobbied for streamlined hemp processing licenses and infrastructure investment in fiber processing facilities.

Civil Society and Advocacy Groups

Organizations including the Human Rights Commission of Pakistan and the Pakistan Medical Association have participated in CCRA consultations. These groups raised concerns about enforcement capacity, potential for regulatory capture, and protection of small farmers' interests. Some advocacy organizations pushed for broader decriminalization of personal cannabis use, which the CCRA Rules do not address.

International Partners

The United Nations Office on Drugs and Crime maintains an office in Pakistan and provides technical assistance on regulatory compliance with international treaties. The U.S. Drug Enforcement Administration coordinates with Pakistani authorities on trafficking interdiction. Israel's Ministry of Agriculture has offered technical cooperation on cannabis cultivation techniques based on its established medical cannabis program.

Legal and Regulatory Framework

The CCRA Rules 2026 establish a comprehensive licensing system for cannabis cultivation, processing, manufacturing, testing, transportation, and export, while maintaining criminal prohibition of recreational use under existing narcotics laws.

Statutory Foundation

The regulatory framework rests on the Cannabis Control and Regulatory Authority Act, 2023, which amended the Control of Narcotic Substances Act, 1997 to create exceptions for licensed cannabis activities. The 2023 act defines industrial hemp as cannabis containing no more than 0.3% delta-9-tetrahydrocannabinol (THC) by dry weight, consistent with international standards adopted by the United States, Canada, and European Union. Medicinal cannabis may contain higher THC levels but requires more stringent licensing and security measures.

The CCRA operates under Section 4 of the 2023 act, which grants authority to "regulate, control, and supervise all aspects of cannabis cultivation, processing, manufacturing, testing, distribution, import, export, and research for industrial, medicinal, and scientific purposes." The act specifies that recreational cannabis remains prohibited under the Control of Narcotic Substances Act, 1997, with penalties including imprisonment up to 25 years for unlicensed cultivation or trafficking.

Licensing Categories

The CCRA Rules establish six license types, each with specific requirements and restrictions:

• Cultivation License (Hemp): Authorizes outdoor cultivation of hemp varieties with THC content below 0.3%. Requires land ownership or lease documentation, security plan, and water rights verification. Valid for three years with annual renewal fees of 100,000 Pakistani rupees (approximately $350).
• Cultivation License (Medicinal): Permits cultivation of higher-THC cannabis for pharmaceutical extraction. Requires indoor or greenhouse facilities with 24-hour security, surveillance systems, and restricted access protocols. Initial license fee of 5 million Pakistani rupees (approximately $17,500) with annual renewals at 2 million rupees.
• Processing License: Authorizes extraction, refinement, and processing of cannabis into oils, isolates, or other intermediate products. Requires good manufacturing practice certification and hazardous materials handling permits. Annual fee of 3 million Pakistani rupees.
• Manufacturing License: Permits production of finished pharmaceutical products, textiles, or other consumer goods containing cannabis derivatives. Requires separate Drug Regulatory Authority of Pakistan approval for pharmaceutical products. Annual fee of 2 million Pakistani rupees.
• Testing Laboratory License: Authorizes analytical testing of cannabis products for potency, contaminants, and quality control. Requires ISO 17025 accreditation and qualified laboratory personnel. Annual fee of 1 million Pakistani rupees.
• Research License: Permits academic and commercial research on cannabis genetics, cultivation, processing, and medical applications. Requires institutional review board approval for human subjects research. Annual fee of 500,000 Pakistani rupees.

Application and Approval Process

License applications must include detailed business plans, financial statements demonstrating capitalization, background checks for all principals and key employees, and site plans showing security measures. The CCRA conducts site inspections before license approval and may impose additional conditions based on location, scale, or other factors. Applications undergo a 90-day review period, with the CCRA required to approve, deny, or request additional information within that timeframe.

Foreign investment in licensed facilities requires approval from the Board of Investment and must maintain Pakistani majority ownership of at least 51%. Foreign technical partnerships and management contracts face no ownership restrictions, allowing international expertise transfer while preserving domestic economic benefits.

Cultivation Standards and Restrictions

The rules designate specific geographic zones for cannabis cultivation based on climate, security, and monitoring feasibility. Khyber Pakhtunkhwa permits cultivation in 12 districts, while Balochistan authorizes 8 districts. Punjab and Sindh provinces remain excluded from cultivation zones pending infrastructure development and law enforcement capacity building.

Hemp cultivation requires certified seed from CCRA-approved sources, primarily PARC-developed varieties. Cultivators must test crops for THC content at flowering stage and pre-harvest, with samples analyzed by CCRA-licensed laboratories. Crops exceeding 0.3% THC must be destroyed under CCRA supervision, with cultivators bearing destruction costs. Three violations within five years result in license revocation.

Medicinal cannabis cultivation must occur in enclosed facilities with controlled access. The rules mandate video surveillance with 90-day retention, visitor logs, and employee background checks. Cultivators must report monthly production volumes, harvest dates, and inventory levels through the CCRA's electronic tracking system.

Track-and-Trace Requirements

All licensed cannabis from cultivation through final sale requires tracking through the CCRA's Cannabis Tracking System (CTS), a blockchain-based platform developed in partnership with the National Database and Registration Authority. Each plant receives a unique identifier at the seedling stage, with subsequent tracking of harvested material, processed products, and finished goods. The system records all transfers between licensed facilities, enabling the CCRA to monitor the entire supply chain and identify diversion points.

Quality Control and Testing

The rules establish mandatory testing protocols for cannabinoid potency, pesticide residues, heavy metals, microbial contaminants, and residual solvents. Hemp products for export must meet importing country standards in addition to CCRA requirements. Medicinal cannabis products require good manufacturing practice compliance and batch testing before release.

The CCRA maintains a list of approved testing laboratories and may conduct random verification testing. Products failing quality standards must be destroyed or remediated under CCRA supervision. Laboratories reporting false results face license suspension or revocation and criminal penalties under the Pakistan Penal Code for fraud.

Export Authorization

Licensed facilities may export hemp fiber, hemp seed, CBD isolate, and pharmaceutical-grade cannabis products to countries with legal import frameworks. Export requires CCRA authorization for each shipment, including documentation of destination country import permits and compliance with international treaty obligations. The Ministry of Commerce issues export licenses based on CCRA certification of product quality and legal compliance.

Penalties and Enforcement

The rules establish administrative penalties for license violations separate from criminal penalties under the Control of Narcotic Substances Act, 1997. Administrative penalties include fines up to 10 million Pakistani rupees, license suspension, and permanent revocation for serious violations. Criminal penalties apply to unlicensed cultivation, diversion to illicit markets, and violations of security requirements, with imprisonment ranging from two to 25 years depending on offense severity.

Market and Business Implications

Pakistan's CCRA Rules create immediate opportunities in pharmaceutical API production, hemp textile manufacturing, and agricultural exports, with the government projecting $1 billion in annual revenue within five years.

Pharmaceutical Sector Opportunities

Pakistan's pharmaceutical industry imports approximately $400 million in active pharmaceutical ingredients annually, including cannabinoid-based compounds for epilepsy medications and pain management products. Domestic CBD and THC production could reduce import dependence and create export opportunities to markets with established medical cannabis programs. The Drug Regulatory Authority of Pakistan has already approved cannabis-derived medicines including Epidiolex for pediatric epilepsy, creating immediate domestic demand for pharmaceutical-grade cannabinoids.

Major pharmaceutical companies have announced investment plans pending CCRA license approval. Getz Pharma, Pakistan's largest pharmaceutical manufacturer with annual revenue exceeding $200 million, has allocated $10 million for a cannabis extraction facility in Karachi. The company plans to produce CBD isolate for domestic formulation and export to European markets. Searle Pakistan has partnered with Israeli cannabis technology company Cannbit to develop cultivation and extraction capabilities targeting Middle Eastern and African export markets.

The pharmaceutical sector faces challenges including technology transfer, quality control infrastructure, and international certification. Good manufacturing practice compliance requires significant capital investment, estimated at $5 million to $15 million per facility for extraction and formulation equipment. International buyers demand certifications including EU GMP or FDA registration, which Pakistani facilities must obtain to access premium export markets.

Textile and Industrial Hemp Applications

Pakistan's textile sector, which contributes 60% of export earnings and employs 15 million workers, views hemp fiber as a sustainable alternative to cotton. Hemp requires significantly less water than cotton—a critical advantage in water-stressed regions—and produces stronger, more durable fiber suitable for apparel, home textiles, and industrial applications. The All Pakistan Textile Mills Association estimates hemp could substitute for 5% to 10% of cotton consumption within a decade, reducing water use by approximately 500 billion liters annually.

Textile manufacturers face infrastructure challenges in hemp processing. Hemp fiber requires specialized decorticating equipment to separate fiber from woody core material, with limited domestic manufacturing capacity. The government has announced plans to establish three hemp processing centers in Faisalabad, Karachi, and Multan with Chinese equipment financing. Initial processing capacity will reach 50,000 metric tons annually, expandable to 200,000 tons based on cultivation growth.

Export markets for Pakistani hemp textiles include European Union countries with strong demand for sustainable materials, and China, which imports hemp fiber for paper and composite manufacturing. The European Union's textile sustainability regulations favor natural fibers over synthetics, creating market opportunities for Pakistani exporters who can meet environmental and social compliance standards.

Agricultural Economics and Rural Development

Hemp cultivation offers higher returns than traditional crops in mountainous regions with limited irrigation. The Ministry of Narcotics Control estimates hemp generates 150,000 to 200,000 Pakistani rupees per hectare (approximately $525 to $700), compared to 80,000 to 100,000 rupees for wheat and 120,000 to 150,000 rupees for maize. Medicinal cannabis cultivation in controlled environments yields significantly higher returns but requires substantial capital investment beyond most small farmers' capacity.

The CCRA has announced contract farming programs connecting licensed processors with smallholder farmers in Khyber Pakhtunkhwa and Balochistan. Processors provide certified seed, technical assistance, and guaranteed purchase agreements, reducing farmer risk while ensuring consistent supply. The Khyber Pakhtunkhwa Agriculture Department estimates 10,000 farming families will participate in contract programs in the first year, expanding to 50,000 families by 2030.

Rural development implications extend beyond direct cultivation income. Processing facilities create employment in transportation, warehousing, and manufacturing. The government projects 100,000 direct jobs in cannabis cultivation and processing within five years, with an additional 200,000 indirect jobs in supporting industries. These employment opportunities concentrate in underdeveloped regions with limited alternative economic activities, potentially reducing migration to urban centers and improving rural living standards.

Investment and Capital Requirements

Licensed cannabis operations require significant upfront capital for land, facilities, equipment, and working capital. Hemp cultivation requires relatively modest investment—approximately 500,000 to 1 million Pakistani rupees per hectare for land preparation, irrigation, and initial inputs. Medicinal cannabis facilities require $2 million to $10 million for greenhouse construction, environmental controls, security systems, and processing equipment.

Pakistani banks have expressed caution regarding cannabis sector financing due to reputational concerns and unclear international banking implications. The State Bank of Pakistan issued guidance in May 2026 clarifying that financing licensed cannabis operations does not violate banking regulations or anti-money laundering requirements. Several banks including Habib Bank Limited and MCB Bank have announced specialized agricultural lending programs for licensed hemp cultivators, with interest rates of 12% to 15% and loan terms up to seven years.

Foreign investment interest has emerged from Chinese agricultural companies, Middle Eastern pharmaceutical firms, and European hemp processors. The Board of Investment has received approximately $150 million in foreign investment proposals for cannabis projects, primarily in extraction and pharmaceutical manufacturing. Most proposals involve technical partnerships with Pakistani majority-owned entities to satisfy ownership requirements.

Tax Revenue Projections

The Ministry of Finance projects cannabis sector tax revenue of 10 billion to 15 billion Pakistani rupees annually (approximately $35 million to $52 million) within five years, rising to 30 billion to 50 billion rupees by 2035. Revenue sources include license fees, production taxes, export duties, and corporate income taxes from licensed businesses. The government has designated 30% of cannabis tax revenue for drug treatment and prevention programs, addressing concerns that legalization might increase substance abuse.

What Experts Say

Pakistani and international experts offer mixed assessments of the CCRA Rules, praising economic potential while raising concerns about enforcement capacity, international treaty compliance, and social implications.

Dr. Khalid Mahmood, director of the Pakistan Agricultural Research Council, described the regulations as "a pragmatic approach to harnessing Pakistan's natural advantages in cannabis cultivation while maintaining appropriate controls." According to Dr. Mahmood, Pakistan's northern regions possess ideal climate and soil conditions for high-quality cannabis production, and the CCRA framework enables farmers to benefit from legal markets rather than risking criminal penalties. He emphasized the importance of certified seed programs and extension services to ensure farmers meet quality standards and THC limits.

Dr. Sania Nishtar, former federal minister for health and currently advising the World Health Organization, expressed support for medical cannabis access while cautioning about implementation challenges. In a June 2026 interview with Dawn newspaper, Dr. Nishtar stated that cannabis-derived medicines offer genuine therapeutic benefits for epilepsy, chronic pain, and other conditions, but require rigorous quality control and physician oversight. She noted that Pakistan's healthcare system lacks training in cannabis medicine and recommended the CCRA develop clinical guidelines and physician education programs.

Major General (Retired) Tariq Khan, CCRA Board chairman, emphasized the authority's commitment to preventing diversion to illicit markets. According to Khan, the track-and-trace system and regular inspections will enable the CCRA to monitor all licensed cannabis from seed to sale. He acknowledged enforcement challenges in remote cultivation areas but expressed confidence that coordination with provincial police and the Anti-Narcotics Force would prevent large-scale diversion.

International drug policy experts have questioned whether Pakistan can effectively implement the regulatory framework given institutional capacity constraints. Dr. Vanda Felbab-Brown, senior fellow at the Brookings Institution and specialist in international drug policy, noted that many countries with stronger regulatory institutions have struggled to prevent cannabis diversion and maintain quality control. According to Dr. Felbab-Brown, Pakistan's success will depend on sustained political commitment, adequate funding for the CCRA, and resistance to corruption pressures.

Martin Jelsma, director of the Drugs and Democracy Program at the Transnational Institute, raised concerns about international treaty compliance. Jelsma noted that the 1961 Single Convention on Narcotic Drugs limits cannabis to medical and scientific purposes, and Pakistan's industrial hemp program may face scrutiny from the International Narcotics Control Board. He suggested that Pakistan should advocate for treaty reform to explicitly permit industrial hemp, as Canada and Uruguay have done.

Pakistani civil society organizations have expressed concerns about social equity and small farmer protection. Karamat Ali, executive director of the Pakistan Institute of Labour Education and Research, stated that licensing fees and capital requirements may exclude small farmers from legal participation, concentrating benefits among wealthy landowners and corporations. Ali recommended the CCRA establish reduced fees and technical assistance programs for smallholders to ensure equitable access to legal markets.

Religious scholars have offered varied perspectives on cannabis regulation. Mufti Muneeb-ur-Rehman, former chairman of the Ruet-e-Hilal Committee, reiterated that intoxicating cannabis use remains prohibited under Islamic law but acknowledged that industrial and medical applications serve legitimate purposes. Other religious leaders have criticized any cannabis legalization as contrary to Islamic principles, though the March 2025 fatwa from the Ministry of Religious Affairs has reduced religious opposition.

What's Next

The CCRA will begin accepting license applications on August 1, 2026, with first licenses expected by October 2026 and initial harvests in spring 2027.

Near-Term Implementation Timeline

The CCRA has published a phased implementation schedule for the coming 18 months. License applications open August 1, 2026, with priority processing for hemp cultivation and processing licenses. The authority expects to approve 50 to 100 hemp cultivation licenses by October 2026, enabling farmers to plant crops for spring 2027 harvest. Medicinal cannabis licenses face longer approval timelines due to security and facility requirements, with first approvals expected in early 2027.

The CCRA will conduct regional information sessions for prospective applicants in Peshawar, Quetta, Lahore, and Karachi during August and September 2026. These sessions will explain application procedures, technical requirements, and compliance obligations. The authority has published application forms and guidance documents on its website and established a helpline for applicant questions.

Provincial agriculture departments will register interested farmers and conduct preliminary site assessments during August 2026. The Khyber Pakhtunkhwa Agriculture Department has identified approximately 5,000 farmers expressing interest in hemp cultivation, with similar numbers in Balochistan. Provincial authorities will provide extension services on cultivation techniques, pest management, and harvest timing to ensure crop quality.

Infrastructure Development

The government has allocated 5 billion Pakistani rupees (approximately $17.5 million) for cannabis sector infrastructure development in fiscal year 2026-2027. Funding priorities include hemp processing facilities, testing laboratories, and CCRA regional offices. The Ministry of Industries and Production will oversee construction of three hemp decorticating facilities in Faisalabad, Karachi, and Multan, with completion targeted for mid-2027.

The CCRA is establishing a central testing laboratory in Islamabad with capacity to analyze 10,000 samples annually for cannabinoid content, pesticides, heavy metals, and microbial contaminants. The laboratory will achieve ISO 17025 accreditation by December 2026 and serve as the reference facility for private testing laboratories. Additional regional laboratories are planned for Peshawar and Quetta pending budget allocation.

International Engagement

Pakistan will submit its first report to the International Narcotics Control Board on licensed cannabis activities in January 2027, as required under the 1961 Single Convention on Narcotic Drugs. The report will detail license issu